David Klein, Click Therapeutics CEO

Boehringer In­gel­heim deep­ens its col­lab­o­ra­tion with Click Ther­a­peu­tics in a deal worth $460M

Boehringer In­gel­heim inked a mas­sive col­lab­o­ra­tion with dig­i­tal ther­a­peu­tics com­pa­ny Click Ther­a­peu­tics two years ago — and now its ex­pand­ing.

On Mon­day, the Ger­man phar­ma an­nounced the launch of an “ex­pand­ed col­lab­o­ra­tion” be­tween Boehringer In­gel­heim and Click to de­vel­op and com­mer­cial­ize a sec­ond “pre­scrip­tion-based dig­i­tal ther­a­peu­tic.” The col­lab­o­ra­tion will cen­ter on schiz­o­phre­nia and aim to com­bine mul­ti­ple ther­a­peu­tic in­ter­ven­tions for use with phar­ma­ceu­ti­cal ther­a­py to help peo­ple with the dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.